Summary
IDEXX Laboratories, Inc. (IDXX) reported strong revenue growth of 16% to $739.1 million for the fiscal year ended December 30, 2006. This growth was primarily driven by its Companion Animal Group (CAG), which saw a 16.4% revenue increase, fueled by instruments, consumables, rapid assays, and laboratory services. The company also experienced robust growth in its Production Animal Segment (PAS), up 31.1%. While gross profit margins remained stable around 51.3%, operating expenses increased, partly due to the adoption of new accounting standards for share-based compensation (SFAS No. 123(R)), which impacted reported expenses and operating income margins. Despite these factors, operating income grew by 10.9% year-over-year. IDEXX continues to invest in research and development, with R&D expenses increasing to 7.3% of sales, signaling a commitment to innovation in diagnostic platforms and new tests. The company also actively pursues strategic acquisitions, notably the recent addition of the Critical Care Division of Osmetech plc for its human point-of-care diagnostics market and the planned acquisition of Institut Pourquier for its production animal diagnostics business. While facing competition and regulatory hurdles, IDEXX's diversified business model across veterinary, water, and production animal health markets, coupled with ongoing product development and strategic acquisitions, positions it for continued growth.
Key Highlights
- 1Revenue increased by 16% to $739.1 million for the fiscal year 2006, driven by strong performance in the Companion Animal Group (CAG) and Production Animal Segment (PAS).
- 2Companion Animal Group (CAG) revenue grew by 16.4%, with significant contributions from instruments, consumables, rapid assays, and laboratory services.
- 3Production Animal Segment (PAS) revenue saw substantial growth of 31.1%, indicating strong demand in international livestock diagnostics.
- 4Research and Development (R&D) expenses increased to $53.6 million (7.3% of revenue), reflecting continued investment in new product development.
- 5The company completed strategic acquisitions, including the Critical Care Division of Osmetech plc (human point-of-care diagnostics) and announced the planned acquisition of Institut Pourquier (production animal diagnostics).
- 6Adoption of SFAS No. 123(R) for share-based compensation starting in 2006 increased operating expenses and reduced reported operating income margins.
- 7Cash flow from operations remained strong at $109.8 million, though impacted by changes in inventory and a shift in accounting for tax benefits from stock options.